Pulse ·

NSW makes MND a notifiable disease — what this means for GPs and patients

By Dr HB Lo, FACRRM 4 min read
Verdict Yes — worth knowing about

NSW has become the first jurisdiction globally to classify motor neurone disease (MND) as a notifiable condition. Clinicians, hospitals, and laboratories must now formally report all MND diagnoses to NSW Health — creating the state's first mandatory disease registry.

MND kills roughly 800 Australians annually, and deaths have tripled since the late 1980s. The registry will track geographic patterns, environmental exposures, and diagnostic delays — data that has never before been collected systematically.

For anyone with an MND diagnosis in NSW: your clinician will report to the registry as routine notification. The goal is better service mapping, not individual surveillance.

What just happened

Medical Republic reported on 26 June 2026 that New South Wales has become the first jurisdiction in the world to classify motor neurone disease (MND) — sometimes called ALS — as a notifiable condition. From this week, every clinician, hospital, and laboratory in NSW must formally report each new MND diagnosis to NSW Health. The data flows into a mandatory disease registry: the first of its kind for MND anywhere globally.

The announcement has been received with what can only be described as controlled relief by the MND research community. Professor Dominic Rowe AM, one of Australia’s leading MND neurologists, called it “a major and landmark step forward in the global fight against MND.” Associate Professor Marco Morsch from the Macquarie MND Research Centre described the registry as enabling researchers to “examine geographic patterns, environmental exposures, diagnostic delays and service needs with enhanced precision” — a list that tells you exactly what has been missing until now.

MND remains one of medicine’s more honest admissions of failure. We cannot cure it. We cannot reliably slow it in most people. We cannot yet explain why 90 to 95 per cent of cases happen at all. That honesty is part of why this registry matters: it is infrastructure for the research that needs to happen before any of that changes.

The both-and

What the registry will — and won’t — fix immediately

The registry is surveillance infrastructure, not a treatment. What it creates is a population-level dataset that has not existed before: who gets MND in NSW, where they live, how long it took to diagnose them, what services they accessed, and what environmental or genetic exposures they share.

Research into environmental clustering — occupational exposures, water quality, proximity to industrial land — has long been limited by the absence of systematic, mandatory notification data. Without it, researchers have been working from voluntary databases and clinical cohorts that cannot reliably represent the whole MND population. The registry changes that.

What it will not do is shorten the time between symptom onset and diagnosis in the short term. Early MND symptoms — muscle weakness, cramps, fasciculations (small visible twitching under the skin), motor skill changes, speech or swallowing difficulties — overlap substantially with other neurological conditions. MND Australia notes that many people spend 12 months or more reaching a confirmed diagnosis. The registry will eventually map those delays and help identify where diagnostic pathways need attention — but that analysis takes years to yield actionable findings, not months.

The 90/10 genetic picture

Roughly 5 to 10 per cent of MND cases are inherited, linked to gene mutations including C9orf72, SOD1, TARDBP, and FUS. The remaining 90 to 95 per cent are sporadic — arising from a combination of genetic susceptibility, environmental exposure, and factors we do not yet understand well.

This matters for families navigating a diagnosis. A first-degree relative with MND does not mean you will develop MND — absolute individual risk remains low. It does mean a conversation with a neurologist or genetic counsellor is worth having, particularly if multiple generations of the same family are affected. Genetic counselling is not about certainty; it is about informed decision-making with the information that currently exists.

The voluntary assisted dying context

MND is one of the conditions most commonly associated with requests for voluntary assisted dying (VAD), which is now legal in all Australian states for eligible patients with a terminal diagnosis and a prognosis of less than 12 months. Roughly 85 per cent of people with MND die from respiratory failure as the breathing muscles weaken over months to years, and the trajectory varies substantially between individuals.

The federal government’s announcement that MND patients will be considered a priority cohort for the Support at Home program is a separate but related development: the funding architecture around community-based care is being restructured alongside the registry, not as an afterthought.

Both developments — the registry and the Support at Home prioritisation — signal that MND is being treated, at the policy level, as a disease that warrants systematic tracking and dedicated resource allocation in a way it has not been before.

2 cents

If you have a family member living with an MND diagnosis in NSW, they will now be included in registry data automatically — reporting is on the clinician, not a separate patient enrolment process.

If you have been noticing persistent muscle weakness, fasciculations (small visible twitching under the skin), or unexplained changes to speech or swallowing that have lasted more than four to six weeks without explanation: speak with your GP. A neurology referral is the appropriate next step. MND is on the differential, but so is a long list of treatable conditions that are worth ruling in or out.

The registry is the beginning of better epidemiology. It is not a treatment. But better epidemiology is how treatments eventually arrive — and Australia is, for the first time, building the infrastructure to generate it.

Verdict: yes — worth knowing about.

Sources cited

  1. Medical Republic — NSW first state to classify MND as a notifiable disease. 26 June 2026. https://www.medicalrepublic.com.au/nsw-first-state-to-classify-mnd-as-a-notifiable-disease/126829
  2. MND Australia — Is there a genetic link to MND? https://www.mndaust.asn.au/What-is-MND/Is-there-a-genetic-link-to-MND.aspx
  3. MND Australia — What happens in MND? https://www.mndaust.asn.au/What-is-MND/What-happens-in-MND.aspx
  4. Australian Government Department of Health — Support at Home program. https://www.health.gov.au/our-work/support-at-home

Frequently asked questions

  • How do I know if my symptoms need GP evaluation for MND?

    The early symptoms of MND — persistent muscle weakness, fasciculations (small visible twitching under the skin), unexplained changes to speech or swallowing, motor skill loss, cramps — overlap with many treatable conditions. If any of these have been present for more than four to six weeks without an explanation, a GP visit is the appropriate next step. Your GP can assess whether a neurology referral is warranted. MND is on the differential diagnosis list for these symptoms, but so are cervical myelopathy, multifocal motor neuropathy, and other conditions that respond well to treatment. Getting checked does not mean assuming the worst-case scenario.

  • Does the NSW MND registry affect patient privacy or insurance?

    Notifiable disease reporting in Australia is governed by state health legislation. NSW Health collects notification data for public health surveillance purposes under the Public Health Act 2010 (NSW). The data is used for epidemiological research and service planning, not shared with insurers or employers. Patient identifiers are held securely within the public health system. If you have concerns about how your specific information will be used, your clinician or NSW Health's public health unit can explain what data is reported and how it is stored.